In stockBestseller
- Batch verified
- Temperature controlled
- Discreet packaging
- Purity
- 99.4%
- Form
- Lyophilised powder
- Molecular weight
- 4813.5 g/mol
- Storage
- -20°C, desiccated, protected from light
- Batch
- B-2408-105
For research use only · Not for human consumption
About this compound
−20.9%
Largest mean weight change reported
15 mg · 72 weeks · placebo −3.1% (1)
−2.30
HbA1c points, type 2 diabetes
15 mg · 40 weeks · semaglutide 1 mg −1.86 (2)
−14.7%
Mean weight change with type 2 diabetes
15 mg · 72 weeks · placebo −3.2% (3)
2
Receptor targets
GIP · GLP-1 (4)
Tirzepatide is a synthetic 39-amino-acid peptide developed by Eli Lilly under the code LY3298176. It is a dual agonist: a single molecule engineered to act at both incretin receptors — GIP and GLP-1 — rather than at GLP-1 alone (4).
Coskun and colleagues described its discovery and first clinical characterisation in Molecular Metabolism in 2018, reporting that it activated signalling at both receptors and produced glucose-dependent insulin secretion in the models they used (4).
The two arms are not engaged equally. Willard and colleagues calculated receptor occupancy at clinically studied doses and reported greater engagement at the GIP receptor than at the GLP-1 receptor — an imbalanced mechanism of action, in their words. At the GLP-1 receptor they also reported biased signalling: cAMP generation favoured over beta-arrestin recruitment, alongside a weaker ability to drive receptor internalisation than GLP-1 itself (5).
That puts tirzepatide in a different position from the rest of this catalogue: it is an authorised medicine rather than an investigational compound. The European Medicines Agency authorised it in the European Union on 15 September 2022, under the name Mounjaro, for type 2 diabetes and for weight management (9).
That authorisation belongs to a licensed medicine, prescribed by a doctor and dispensed by a pharmacy. It does not extend to the vial on this page. Peptio is not a pharmacy and supplies research material only, and every figure here describes what happened to participants in a published trial rather than a protocol for anyone to follow.
Two receptor targets
GIP
Glucose-dependent insulinotropic polypeptide receptor
The arm that separates tirzepatide from the GLP-1 peptides before it. Willard and colleagues reported that at this receptor tirzepatide mimics the actions of native GIP, and that receptor occupancy at clinically studied doses was greater here than at the GLP-1 receptor (5).
GLP-1
Glucagon-like peptide-1 receptor
The single target Semaglutide acts on, and the arm associated in the published work with reduced calorie intake and slowed gastric emptying. Tirzepatide engages it differently from GLP-1 itself: the same work reported signalling biased towards cAMP generation over beta-arrestin recruitment, with a weaker ability to drive receptor internalisation (5).
Mean weight change by dose, at 72 weeks
One trial, 2,539 adults, 72 weeks. Unlike the comparison further down, every bar here comes from the same trial, so they are directly comparable to each other. Its participants had obesity, or overweight with a weight-related complication other than diabetes.
Placebo
−3.1%
5 mg
−15%
10 mg
−19.5%
15 mg
−20.9%
Sources. (1) Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. Figures are the mean percentage change in body weight at 72 weeks in SURMOUNT-1. Tirzepatide is authorised as a medicine in the European Union (9); the material supplied here is not that medicine and is for research use only.
What the Phase 3 programmes reported
Tirzepatide has been through two large Phase 3 programmes — SURMOUNT in obesity and SURPASS in type 2 diabetes. SURMOUNT-1 randomised 2,539 adults over 72 weeks and reported a mean body weight change of −20.9% at 15 mg against −3.1% on placebo (1). SURMOUNT-2 ran 938 adults who also had type 2 diabetes over the same 72 weeks and reported least-squares mean changes of −12.8% at 10 mg and −14.7% at 15 mg against −3.2% on placebo (3).
SURPASS-2 is the unusual one. It randomised 1,879 adults with type 2 diabetes over 40 weeks and set tirzepatide directly against semaglutide 1 mg inside a single trial: HbA1c fell by 2.30 percentage points at 15 mg against 1.86 on semaglutide, and body weight fell further on tirzepatide by a least-squares mean estimated treatment difference of −1.9 kg, −3.6 kg and −5.5 kg at 5, 10 and 15 mg respectively (2). Because both arms sat inside one randomised trial, that is a directly measured comparison rather than two separate results read side by side.
Largest mean weight change reported, by compound
Each bar comes from a different trial, and the trials differ in phase, length, population and design — so these are not head-to-head results. Each placebo arm is the one from that bar's own trial.
Retatrutide 12 mg, 48 wks
−24.2%
placebo arm, same trial −2.1%
Tirzepatide 15 mg, 72 wks
−20.9%
placebo arm, same trial −3.1%
Semaglutide 2.4 mg, 68 wks
−14.9%
placebo arm, same trial −2.4%
Sources. (1) Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. (6) Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. (7) Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. The retatrutide bar comes from a Phase 2 trial and the other two from Phase 3 trials. Tirzepatide is authorised as a medicine in the European Union (9); the material supplied here is not that medicine and is for research use only.
Against the other incretin peptides in this catalogue
Each column reports figures from a different published trial, and the trials differ in phase, length, population and design — so the columns are not a head-to-head comparison. There is one genuine exception, and it is worth stating plainly: SURPASS-2 randomised Tirzepatide against Semaglutide inside a single trial, which makes the two figures in the HbA1c row directly comparable to each other. Nothing else in the table is.
| Parameter | Tirzepatide | Semaglutide | Retatrutide |
|---|---|---|---|
| Receptor targets | GIP and GLP-1 | GLP-1 | GLP-1, GIP and glucagon |
| Weight trial cited here | SURMOUNT-1, Phase 3, 2,539 adults, 72 weeks (1) | STEP 1, Phase 3, 1,961 adults, 68 weeks (6) | Phase 2, 338 adults, 48 weeks (7) |
| Largest mean weight change reported | −20.9% (15 mg) | −14.9% (2.4 mg) | −24.2% (12 mg) |
| Placebo arm in the same trial | −3.1% | −2.4% | −2.1% |
| HbA1c change in type 2 diabetes | −2.30 points at 40 weeks, 15 mg (2) | −1.86 points at 40 weeks, 1 mg (2) | −2.02 points at 24 weeks, 12 mg (Phase 2, 281 adults) (8) |
| Head-to-head evidence cited here | SURPASS-2 randomised it against Semaglutide, 1,879 adults, 40 weeks (2) | The comparator arm in SURPASS-2, at 1 mg (2) | No head-to-head trial against either compound is cited on this page |
| Regulatory status of the medicine | Authorised in the EU as Mounjaro, 15 September 2022 (9) | Authorised in the EU as Wegovy, 6 January 2022 (10) | Investigational; Phase 2 results published (7, 8) |
| Administration in the cited trials | Once weekly, subcutaneous | Once weekly, subcutaneous | Once weekly, subcutaneous |
Sources. (1) Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. (2) Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503–515. (6) Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. (7) Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. (8) Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544. (9) European Medicines Agency. Mounjaro (tirzepatide): European public assessment report; marketing authorisation issued 15 September 2022. (10) European Medicines Agency. Wegovy (semaglutide): European public assessment report; marketing authorisation issued 6 January 2022. Cited elsewhere on this page: (3) Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613–626. (4) Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14. (5) Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. The regulatory row describes the licensed medicines named in it; it does not describe the research material supplied here.
What Peptio ships
A sealed vial of lyophilised powder, in a 5 mg or a 10 mg size. Both are the same material; the difference is the mass in the vial, not the concentration — concentration is set later, by how much solvent is added.
Each batch is released against a certificate of analysis from an independent issuer, and the batch number printed on the vial matches the number on that certificate. Checking those two against each other is the most useful thing to do with a delivery. The purity, form, storage condition and molecular weight recorded for the current batch are in the specifications above.
Handling is the same as for every other compound in the catalogue. The handling protocol below covers storage temperatures, solvent choice and the concentration calculation.
Research use only
Tirzepatide is authorised as a medicine in the European Union, under the name Mounjaro. That authorisation belongs to a licensed pharmaceutical product, prescribed and dispensed through pharmacies; it does not extend to the material sold here. Peptio is not a pharmacy and supplies this compound for research use only — not for human or veterinary consumption. Everything reported on this page comes from published trials and describes their participants; none of it is guidance for use in people, and Peptio publishes no protocol.
Handling and storage
Every compound Peptio ships arrives as a sealed vial of lyophilised powder. Freeze-drying is what keeps it stable in transit: with the water removed and the vial closed, the peptide keeps far longer than it would in solution. The protocol below applies to all of them, and it is the same protocol whichever compound is in the vial.
The steps that matter most happen in the first few minutes after a vial is opened, and in how the prepared solution is labelled afterwards. A vial with no recorded solvent volume is a vial with no known concentration, and no amount of care later recovers that.
From delivery to prepared solution
01
Inspect on arrival
Check that the crimp seal and stopper are intact and that the powder cake is dry and unbroken. Compare the batch number printed on the vial with the number on the certificate of analysis. A cake that has slumped into a film, or a vial that arrives loose in its packaging, is worth photographing before anything else is done to it.
02
Equilibrate before opening
Let a vial taken from cold storage stand sealed until it reaches room temperature. Opening cold glass in a warm room pulls condensation onto it, and moisture is the one thing a desiccated powder is being protected from.
03
Add the solvent
Direct the solvent slowly down the inner wall of the vial rather than onto the cake, then let it dissolve on its own and swirl gently until the solution runs clear. This takes a minute or two, and it is not helped by shaking.
04
Label, then refrigerate
Write the date, the solvent and the exact volume added onto the vial before it goes anywhere. Keep the prepared solution cold and out of direct light, and check that it is still clear each time it is used.
Quick reference
- Form
- Lyophilised powder in a sealed, stoppered vial
- Solvent
- Bacteriostatic water where the vial will be drawn from more than once; sterile water where it will not
- Typical reconstitution volume
- 1–3 mL, chosen to give the concentration the work calls for
- Storage before reconstitution
- −20 °C, desiccated and protected from light
- Storage after reconstitution
- 2–8 °C, protected from light, in the original stoppered vial
- In transit
- Short periods at 2–8 °C are expected; that is what the insulated mailer is for
- Once opened
- Record the date on the vial. How long a prepared solution stays usable depends on the solvent and the storage temperature, so the date is the only reliable reference point.
Handling
| Correct | Common mistake |
|---|---|
| Direct the solvent down the inner wall of the vial and let the cake dissolve on its own. | Drive the solvent onto the powder in a fast stream. |
| Swirl gently until the solution runs clear. | Shake or vortex the vial — mechanical agitation and foaming degrade peptide structure. |
| Let a vial from cold storage reach room temperature while it is still sealed. | Open a vial straight out of the freezer, and pull condensation into a product that is kept dry on purpose. |
| Label every prepared vial with the date, the solvent and the volume added. | Rely on memory — two vials that look identical at 2–8 °C can hold two different concentrations. |
| Draw through the stopper with a fresh sterile needle each time. | Prise off the crimp seal; an open vial cannot be kept sterile. |
| Keep prepared solution cold and shielded from light between uses. | Leave a reconstituted vial standing at room temperature on the bench. |
| Look at the solution before every use and confirm it is clear. | Use a solution that has turned cloudy or thrown a visible particle. |
Solvent volume sets the concentration
The mass of peptide in a vial is fixed at manufacture. The only variable is how much solvent goes in, and it changes every measurement that follows — 2 mL instead of 1 mL halves the concentration. Confirm the vial's usable capacity before adding anything, since a 2 mL vial will not take 3 mL, and write down the volume you actually added.
Working out the concentration
- Concentration (mg/mL) = peptide mass in the vial (mg) ÷ solvent volume added (mL).
- A 5 mg vial with 1 mL of solvent gives 5 mg/mL. The same vial with 2 mL gives 2.5 mg/mL.
- A 10 mg vial with 2 mL of solvent also gives 5 mg/mL — the same concentration from twice the mass.
- Volume (mL) = mass required (mg) ÷ concentration (mg/mL).
- 1 mg/mL is 1,000 micrograms per mL. Convert once, at the start, and hold one unit for the whole calculation.
Questions
About Tirzepatide
Delivery
- One delivery option at checkout: standard, 3–5 working days.
- Orders ship in an insulated mailer.
- Delivery is free on orders over €150.00.
- See the Shipping page for the delivery terms in full.
Customer reviews
0.0
0 reviews
- 50
- 40
- 30
- 20
- 10
No reviews yet.
Related compounds
In stockNew
In stock
In stock